Skip to main content

Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method.

Publication ,  Journal Article
Bayliff, S; Horvatinovich, JM; Gong, JZ; Rosoff, PM
Published in: J Pediatr Hematol Oncol
September 2003

It is currently thought that approximately 1% of children with Down syndrome will develop a "premalignant" syndrome known as transient myeloproliferative disorder (TMD). Prospective, population-based studies of the incidence of TMD in Down syndrome infants is lacking. Although most cases of TMD resolve by 1 year of age, data suggest that 10% to 20% of Down syndrome patients with TMD develop AML-M7 (megakaryoblastic leukemia). To identify the true incidence of TMD in the Down syndrome population, a sensitive, rapid, and cost-effective method of quantifying circulating megakaryoblasts in large numbers of patients was needed. In this pilot study, the authors tested the hypothesis that there are fewer than 1% megakaryoblasts of nucleated cells circulating in the blood of normosomic infants. Four-antigen flow cytometry was used to establish the percentage of megakaryoblasts present in each of 100 cord blood samples collected blindly from "normosomic" live births. There was a mean percentage of 0.017% megakaryoblasts in 100 cord blood samples from normosomic infants. Flow cytometry proved to be a sensitive, rapid, and reproducible method for the quantification of megakaryoblasts. Less than 1% of circulating nucleated cells in the blood of newborn infants are megakaryoblasts, providing a comparison population for the authors' larger proposed incidence study.

Duke Scholars

Published In

J Pediatr Hematol Oncol

DOI

ISSN

1077-4114

Publication Date

September 2003

Volume

25

Issue

9

Start / End Page

721 / 725

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Reference Values
  • Preleukemia
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Myeloproliferative Disorders
  • Megakaryocytes
  • Infant, Newborn
  • Incidence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bayliff, S., Horvatinovich, J. M., Gong, J. Z., & Rosoff, P. M. (2003). Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method. J Pediatr Hematol Oncol, 25(9), 721–725. https://doi.org/10.1097/00043426-200309000-00009
Bayliff, Sherry, Joseph M. Horvatinovich, Jerald Z. Gong, and Philip M. Rosoff. “Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method.J Pediatr Hematol Oncol 25, no. 9 (September 2003): 721–25. https://doi.org/10.1097/00043426-200309000-00009.
Bayliff S, Horvatinovich JM, Gong JZ, Rosoff PM. Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method. J Pediatr Hematol Oncol. 2003 Sep;25(9):721–5.
Bayliff, Sherry, et al. “Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method.J Pediatr Hematol Oncol, vol. 25, no. 9, Sept. 2003, pp. 721–25. Pubmed, doi:10.1097/00043426-200309000-00009.
Bayliff S, Horvatinovich JM, Gong JZ, Rosoff PM. Lack of circulating megakaryoblasts in newborn peripheral blood: development and validation of a sensitive flow cytometric detection method. J Pediatr Hematol Oncol. 2003 Sep;25(9):721–725.

Published In

J Pediatr Hematol Oncol

DOI

ISSN

1077-4114

Publication Date

September 2003

Volume

25

Issue

9

Start / End Page

721 / 725

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Reference Values
  • Preleukemia
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Myeloproliferative Disorders
  • Megakaryocytes
  • Infant, Newborn
  • Incidence